Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Change in Receivables (2016 - 2025)

Regenxbio has reported Change in Receivables over the past 12 years, most recently at $561000.0 for Q4 2025.

  • Quarterly results put Change in Receivables at $561000.0 for Q4 2025, up 106.9% from a year ago — trailing twelve months through Dec 2025 was $7.7 million (up 178.92% YoY), and the annual figure for FY2025 was $7.7 million, up 178.92%.
  • Change in Receivables for Q4 2025 was $561000.0 at Regenxbio, down from $6.3 million in the prior quarter.
  • Over the last five years, Change in Receivables for RGNX hit a ceiling of $10.7 million in Q2 2022 and a floor of -$22.0 million in Q4 2021.
  • Median Change in Receivables over the past 5 years was -$505500.0 (2025), compared with a mean of -$1.2 million.
  • Biggest five-year swings in Change in Receivables: tumbled 251.61% in 2022 and later skyrocketed 788.73% in 2025.
  • Regenxbio's Change in Receivables stood at -$22.0 million in 2021, then skyrocketed by 77.99% to -$4.8 million in 2022, then skyrocketed by 30.45% to -$3.4 million in 2023, then crashed by 141.41% to -$8.1 million in 2024, then skyrocketed by 106.9% to $561000.0 in 2025.
  • The last three reported values for Change in Receivables were $561000.0 (Q4 2025), $6.3 million (Q3 2025), and $2.4 million (Q2 2025) per Business Quant data.